clinical trial · NCT07359859
A Study of Ruxolitinib for Preventing Graft-Versus-Host Disease in People With a Hematologic Malignancy Who Will Receive a Stem Cell Transplant
Hematologic MalignanciesCyclophosphamideCyclophosphamideMycophenolate MofetilRuxolitinibTacrolimusTacrolimus
brief summary
The researchers are doing this study to compare 2 different GVHD prevention (prophylaxis) approaches. The researchers will see which approach is good or more effective at preventing chronic GVHD until 1 year after allogeneic hematopoietic stem cell transplantation (allo-HCT).
started
Jan 20, 2026
primary completion
Jan 1, 2029
completion
Jan 1, 2029
last updated
Feb 17, 2026
official title
Randomized Pilot Study of Ruxolitinib for Switch-Maintenance Prophylaxis of Graft-versus-Host Disease in Allogeneic Hematopoietic Cell Transplantation After Intermediate-Dose Post-Transplant Cyclophosphamide (Rux Switch-Maintenance in Intermediate PTCY: RuSMa-PTCY) in Comparison to Full-Dose PTCY
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol